A Beta-containing bivalent SARS-CoV-2 spike protein vaccine candidate with AS03 elicits durable and broad neutralization of variants including Omicron in macaques and confers protection in hamsters Article Swipe
Catherine Berry
,
Vincent Pavot
,
Natalie G. Anosova
,
Michael Kishko
,
De-An Huang
,
Tim Tibbitts
,
Alice Raillard
,
Sylviane Gautheron
,
Sheila Cummings
,
Dinesh S. Bangari
,
Swagata Kar
,
Caroline Atyeo
,
Yixiang Deng
,
Galit Alter
,
Cindy Gutzeit
,
Marguerite Koutsoukos
,
Roman M. Chicz
,
Valérie Lecouturier
·
YOU?
·
· 2022
· Open Access
·
· DOI: https://doi.org/10.21203/rs.3.rs-1928234/v1
YOU?
·
· 2022
· Open Access
·
· DOI: https://doi.org/10.21203/rs.3.rs-1928234/v1
Background Since the beginning of the COVID-19 pandemic, several variants of concern (VOC) have emerged for which there is evidence of an increase in transmissibility, more severe disease, and/or reduced vaccine effectiveness. Effective COVID-19 vaccine strategies are required to achieve broad protective immunity against current and future VOC.Methods We conducted immunogenicity and challenge studies in macaques and hamsters using a bivalent recombinant vaccine formulation containing the SARS-CoV-2 prefusion-stabilized Spike trimers of the parental D614 and the Beta (B.1.351) strains with AS03 adjuvant (CoV2 preS dTM-AS03) in a primary immunization setting. Results We show that a primary immunization with the bivalent CoV2 preS dTM-AS03 elicits broader and durable neutralizing antibody responses against VOC including Omicron BA.1, and SARS-CoV-1 as compared to the parental D614 or Beta variant monovalent vaccines in naïve non-human primates. In addition, the bivalent formulation confers protection against viral challenge with SARS-CoV-2 parental D614G strain as well as Alpha and Beta variant strains in hamsters. Conclusions Our findings demonstrate the potential of a Beta-containing bivalent CoV2 preS dTM-AS03 formulation to provide broad and stable immunogenicity, as well as protection against VOC in naïve populations.
Related Topics
Concepts
Bivalent (engine)
Virology
Neutralization
Spike Protein
Coronavirus disease 2019 (COVID-19)
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
Biology
Chemistry
Virus
Medicine
Infectious disease (medical specialty)
Pathology
Disease
Metal
Organic chemistry
Metadata
- Type
- preprint
- Language
- en
- Landing Page
- https://doi.org/10.21203/rs.3.rs-1928234/v1
- https://www.researchsquare.com/article/rs-1928234/latest.pdf
- OA Status
- gold
- Cited By
- 1
- References
- 43
- Related Works
- 10
- OpenAlex ID
- https://openalex.org/W4294301169
All OpenAlex metadata
Raw OpenAlex JSON
- OpenAlex ID
-
https://openalex.org/W4294301169Canonical identifier for this work in OpenAlex
- DOI
-
https://doi.org/10.21203/rs.3.rs-1928234/v1Digital Object Identifier
- Title
-
A Beta-containing bivalent SARS-CoV-2 spike protein vaccine candidate with AS03 elicits durable and broad neutralization of variants including Omicron in macaques and confers protection in hamstersWork title
- Type
-
preprintOpenAlex work type
- Language
-
enPrimary language
- Publication year
-
2022Year of publication
- Publication date
-
2022-09-02Full publication date if available
- Authors
-
Catherine Berry, Vincent Pavot, Natalie G. Anosova, Michael Kishko, De-An Huang, Tim Tibbitts, Alice Raillard, Sylviane Gautheron, Sheila Cummings, Dinesh S. Bangari, Swagata Kar, Caroline Atyeo, Yixiang Deng, Galit Alter, Cindy Gutzeit, Marguerite Koutsoukos, Roman M. Chicz, Valérie LecouturierList of authors in order
- Landing page
-
https://doi.org/10.21203/rs.3.rs-1928234/v1Publisher landing page
- PDF URL
-
https://www.researchsquare.com/article/rs-1928234/latest.pdfDirect link to full text PDF
- Open access
-
YesWhether a free full text is available
- OA status
-
goldOpen access status per OpenAlex
- OA URL
-
https://www.researchsquare.com/article/rs-1928234/latest.pdfDirect OA link when available
- Concepts
-
Bivalent (engine), Virology, Neutralization, Spike Protein, Coronavirus disease 2019 (COVID-19), Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Biology, Chemistry, Virus, Medicine, Infectious disease (medical specialty), Pathology, Disease, Metal, Organic chemistryTop concepts (fields/topics) attached by OpenAlex
- Cited by
-
1Total citation count in OpenAlex
- Citations by year (recent)
-
2022: 1Per-year citation counts (last 5 years)
- References (count)
-
43Number of works referenced by this work
- Related works (count)
-
10Other works algorithmically related by OpenAlex
Full payload
| id | https://openalex.org/W4294301169 |
|---|---|
| doi | https://doi.org/10.21203/rs.3.rs-1928234/v1 |
| ids.doi | https://doi.org/10.21203/rs.3.rs-1928234/v1 |
| ids.openalex | https://openalex.org/W4294301169 |
| fwci | 0.1251818 |
| type | preprint |
| title | A Beta-containing bivalent SARS-CoV-2 spike protein vaccine candidate with AS03 elicits durable and broad neutralization of variants including Omicron in macaques and confers protection in hamsters |
| biblio.issue | |
| biblio.volume | |
| biblio.last_page | |
| biblio.first_page | |
| topics[0].id | https://openalex.org/T10118 |
| topics[0].field.id | https://openalex.org/fields/27 |
| topics[0].field.display_name | Medicine |
| topics[0].score | 1.0 |
| topics[0].domain.id | https://openalex.org/domains/4 |
| topics[0].domain.display_name | Health Sciences |
| topics[0].subfield.id | https://openalex.org/subfields/2725 |
| topics[0].subfield.display_name | Infectious Diseases |
| topics[0].display_name | SARS-CoV-2 and COVID-19 Research |
| topics[1].id | https://openalex.org/T10041 |
| topics[1].field.id | https://openalex.org/fields/27 |
| topics[1].field.display_name | Medicine |
| topics[1].score | 0.9916999936103821 |
| topics[1].domain.id | https://openalex.org/domains/4 |
| topics[1].domain.display_name | Health Sciences |
| topics[1].subfield.id | https://openalex.org/subfields/2725 |
| topics[1].subfield.display_name | Infectious Diseases |
| topics[1].display_name | COVID-19 Clinical Research Studies |
| topics[2].id | https://openalex.org/T11754 |
| topics[2].field.id | https://openalex.org/fields/27 |
| topics[2].field.display_name | Medicine |
| topics[2].score | 0.9829000234603882 |
| topics[2].domain.id | https://openalex.org/domains/4 |
| topics[2].domain.display_name | Health Sciences |
| topics[2].subfield.id | https://openalex.org/subfields/2725 |
| topics[2].subfield.display_name | Infectious Diseases |
| topics[2].display_name | SARS-CoV-2 detection and testing |
| is_xpac | False |
| apc_list | |
| apc_paid | |
| concepts[0].id | https://openalex.org/C2776620830 |
| concepts[0].level | 3 |
| concepts[0].score | 0.7960183620452881 |
| concepts[0].wikidata | https://www.wikidata.org/wiki/Q4919211 |
| concepts[0].display_name | Bivalent (engine) |
| concepts[1].id | https://openalex.org/C159047783 |
| concepts[1].level | 1 |
| concepts[1].score | 0.7787840366363525 |
| concepts[1].wikidata | https://www.wikidata.org/wiki/Q7215 |
| concepts[1].display_name | Virology |
| concepts[2].id | https://openalex.org/C14086860 |
| concepts[2].level | 3 |
| concepts[2].score | 0.7533122897148132 |
| concepts[2].wikidata | https://www.wikidata.org/wiki/Q337120 |
| concepts[2].display_name | Neutralization |
| concepts[3].id | https://openalex.org/C2909509916 |
| concepts[3].level | 5 |
| concepts[3].score | 0.6537231802940369 |
| concepts[3].wikidata | https://www.wikidata.org/wiki/Q22329850 |
| concepts[3].display_name | Spike Protein |
| concepts[4].id | https://openalex.org/C3008058167 |
| concepts[4].level | 4 |
| concepts[4].score | 0.49895358085632324 |
| concepts[4].wikidata | https://www.wikidata.org/wiki/Q84263196 |
| concepts[4].display_name | Coronavirus disease 2019 (COVID-19) |
| concepts[5].id | https://openalex.org/C3007834351 |
| concepts[5].level | 5 |
| concepts[5].score | 0.4965890049934387 |
| concepts[5].wikidata | https://www.wikidata.org/wiki/Q82069695 |
| concepts[5].display_name | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) |
| concepts[6].id | https://openalex.org/C86803240 |
| concepts[6].level | 0 |
| concepts[6].score | 0.46124476194381714 |
| concepts[6].wikidata | https://www.wikidata.org/wiki/Q420 |
| concepts[6].display_name | Biology |
| concepts[7].id | https://openalex.org/C185592680 |
| concepts[7].level | 0 |
| concepts[7].score | 0.3227840065956116 |
| concepts[7].wikidata | https://www.wikidata.org/wiki/Q2329 |
| concepts[7].display_name | Chemistry |
| concepts[8].id | https://openalex.org/C2522874641 |
| concepts[8].level | 2 |
| concepts[8].score | 0.20329156517982483 |
| concepts[8].wikidata | https://www.wikidata.org/wiki/Q808 |
| concepts[8].display_name | Virus |
| concepts[9].id | https://openalex.org/C71924100 |
| concepts[9].level | 0 |
| concepts[9].score | 0.19252556562423706 |
| concepts[9].wikidata | https://www.wikidata.org/wiki/Q11190 |
| concepts[9].display_name | Medicine |
| concepts[10].id | https://openalex.org/C524204448 |
| concepts[10].level | 3 |
| concepts[10].score | 0.18128415942192078 |
| concepts[10].wikidata | https://www.wikidata.org/wiki/Q788926 |
| concepts[10].display_name | Infectious disease (medical specialty) |
| concepts[11].id | https://openalex.org/C142724271 |
| concepts[11].level | 1 |
| concepts[11].score | 0.0 |
| concepts[11].wikidata | https://www.wikidata.org/wiki/Q7208 |
| concepts[11].display_name | Pathology |
| concepts[12].id | https://openalex.org/C2779134260 |
| concepts[12].level | 2 |
| concepts[12].score | 0.0 |
| concepts[12].wikidata | https://www.wikidata.org/wiki/Q12136 |
| concepts[12].display_name | Disease |
| concepts[13].id | https://openalex.org/C544153396 |
| concepts[13].level | 2 |
| concepts[13].score | 0.0 |
| concepts[13].wikidata | https://www.wikidata.org/wiki/Q11426 |
| concepts[13].display_name | Metal |
| concepts[14].id | https://openalex.org/C178790620 |
| concepts[14].level | 1 |
| concepts[14].score | 0.0 |
| concepts[14].wikidata | https://www.wikidata.org/wiki/Q11351 |
| concepts[14].display_name | Organic chemistry |
| keywords[0].id | https://openalex.org/keywords/bivalent |
| keywords[0].score | 0.7960183620452881 |
| keywords[0].display_name | Bivalent (engine) |
| keywords[1].id | https://openalex.org/keywords/virology |
| keywords[1].score | 0.7787840366363525 |
| keywords[1].display_name | Virology |
| keywords[2].id | https://openalex.org/keywords/neutralization |
| keywords[2].score | 0.7533122897148132 |
| keywords[2].display_name | Neutralization |
| keywords[3].id | https://openalex.org/keywords/spike-protein |
| keywords[3].score | 0.6537231802940369 |
| keywords[3].display_name | Spike Protein |
| keywords[4].id | https://openalex.org/keywords/coronavirus-disease-2019 |
| keywords[4].score | 0.49895358085632324 |
| keywords[4].display_name | Coronavirus disease 2019 (COVID-19) |
| keywords[5].id | https://openalex.org/keywords/severe-acute-respiratory-syndrome-coronavirus-2 |
| keywords[5].score | 0.4965890049934387 |
| keywords[5].display_name | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) |
| keywords[6].id | https://openalex.org/keywords/biology |
| keywords[6].score | 0.46124476194381714 |
| keywords[6].display_name | Biology |
| keywords[7].id | https://openalex.org/keywords/chemistry |
| keywords[7].score | 0.3227840065956116 |
| keywords[7].display_name | Chemistry |
| keywords[8].id | https://openalex.org/keywords/virus |
| keywords[8].score | 0.20329156517982483 |
| keywords[8].display_name | Virus |
| keywords[9].id | https://openalex.org/keywords/medicine |
| keywords[9].score | 0.19252556562423706 |
| keywords[9].display_name | Medicine |
| keywords[10].id | https://openalex.org/keywords/infectious-disease |
| keywords[10].score | 0.18128415942192078 |
| keywords[10].display_name | Infectious disease (medical specialty) |
| language | en |
| locations[0].id | doi:10.21203/rs.3.rs-1928234/v1 |
| locations[0].is_oa | True |
| locations[0].source | |
| locations[0].license | cc-by |
| locations[0].pdf_url | https://www.researchsquare.com/article/rs-1928234/latest.pdf |
| locations[0].version | acceptedVersion |
| locations[0].raw_type | posted-content |
| locations[0].license_id | https://openalex.org/licenses/cc-by |
| locations[0].is_accepted | True |
| locations[0].is_published | False |
| locations[0].raw_source_name | |
| locations[0].landing_page_url | https://doi.org/10.21203/rs.3.rs-1928234/v1 |
| indexed_in | crossref |
| authorships[0].author.id | https://openalex.org/A5026438647 |
| authorships[0].author.orcid | https://orcid.org/0000-0002-7446-0443 |
| authorships[0].author.display_name | Catherine Berry |
| authorships[0].countries | MX |
| authorships[0].affiliations[0].institution_ids | https://openalex.org/I4210150276 |
| authorships[0].affiliations[0].raw_affiliation_string | Sanofi Pasteur, Marcy l'Etoile |
| authorships[0].institutions[0].id | https://openalex.org/I4210150276 |
| authorships[0].institutions[0].ror | https://ror.org/05wd66v55 |
| authorships[0].institutions[0].type | company |
| authorships[0].institutions[0].lineage | https://openalex.org/I3018075036, https://openalex.org/I4210150276 |
| authorships[0].institutions[0].country_code | MX |
| authorships[0].institutions[0].display_name | Sanofi (Mexico) |
| authorships[0].author_position | first |
| authorships[0].raw_author_name | Catherine Berry |
| authorships[0].is_corresponding | False |
| authorships[0].raw_affiliation_strings | Sanofi Pasteur, Marcy l'Etoile |
| authorships[1].author.id | https://openalex.org/A5084625974 |
| authorships[1].author.orcid | https://orcid.org/0000-0002-7362-643X |
| authorships[1].author.display_name | Vincent Pavot |
| authorships[1].countries | MX |
| authorships[1].affiliations[0].institution_ids | https://openalex.org/I4210150276 |
| authorships[1].affiliations[0].raw_affiliation_string | Sanofi Pasteur, Marcy l'Etoile |
| authorships[1].institutions[0].id | https://openalex.org/I4210150276 |
| authorships[1].institutions[0].ror | https://ror.org/05wd66v55 |
| authorships[1].institutions[0].type | company |
| authorships[1].institutions[0].lineage | https://openalex.org/I3018075036, https://openalex.org/I4210150276 |
| authorships[1].institutions[0].country_code | MX |
| authorships[1].institutions[0].display_name | Sanofi (Mexico) |
| authorships[1].author_position | middle |
| authorships[1].raw_author_name | Vincent Pavot |
| authorships[1].is_corresponding | False |
| authorships[1].raw_affiliation_strings | Sanofi Pasteur, Marcy l'Etoile |
| authorships[2].author.id | https://openalex.org/A5021223240 |
| authorships[2].author.orcid | https://orcid.org/0000-0002-1920-8245 |
| authorships[2].author.display_name | Natalie G. Anosova |
| authorships[2].countries | MX |
| authorships[2].affiliations[0].institution_ids | https://openalex.org/I4210150276 |
| authorships[2].affiliations[0].raw_affiliation_string | Sanofi Pasteur |
| authorships[2].institutions[0].id | https://openalex.org/I4210150276 |
| authorships[2].institutions[0].ror | https://ror.org/05wd66v55 |
| authorships[2].institutions[0].type | company |
| authorships[2].institutions[0].lineage | https://openalex.org/I3018075036, https://openalex.org/I4210150276 |
| authorships[2].institutions[0].country_code | MX |
| authorships[2].institutions[0].display_name | Sanofi (Mexico) |
| authorships[2].author_position | middle |
| authorships[2].raw_author_name | Natalie Anosova |
| authorships[2].is_corresponding | False |
| authorships[2].raw_affiliation_strings | Sanofi Pasteur |
| authorships[3].author.id | https://openalex.org/A5017747677 |
| authorships[3].author.orcid | |
| authorships[3].author.display_name | Michael Kishko |
| authorships[3].countries | MX |
| authorships[3].affiliations[0].institution_ids | https://openalex.org/I4210150276 |
| authorships[3].affiliations[0].raw_affiliation_string | Sanofi Pasteur |
| authorships[3].institutions[0].id | https://openalex.org/I4210150276 |
| authorships[3].institutions[0].ror | https://ror.org/05wd66v55 |
| authorships[3].institutions[0].type | company |
| authorships[3].institutions[0].lineage | https://openalex.org/I3018075036, https://openalex.org/I4210150276 |
| authorships[3].institutions[0].country_code | MX |
| authorships[3].institutions[0].display_name | Sanofi (Mexico) |
| authorships[3].author_position | middle |
| authorships[3].raw_author_name | Michael Kishko |
| authorships[3].is_corresponding | False |
| authorships[3].raw_affiliation_strings | Sanofi Pasteur |
| authorships[4].author.id | https://openalex.org/A5052829033 |
| authorships[4].author.orcid | https://orcid.org/0000-0002-6945-7768 |
| authorships[4].author.display_name | De-An Huang |
| authorships[4].affiliations[0].raw_affiliation_string | Sanofi |
| authorships[4].author_position | middle |
| authorships[4].raw_author_name | Dean Huang |
| authorships[4].is_corresponding | False |
| authorships[4].raw_affiliation_strings | Sanofi |
| authorships[5].author.id | https://openalex.org/A5017108834 |
| authorships[5].author.orcid | |
| authorships[5].author.display_name | Tim Tibbitts |
| authorships[5].countries | MX |
| authorships[5].affiliations[0].institution_ids | https://openalex.org/I4210150276 |
| authorships[5].affiliations[0].raw_affiliation_string | Sanofi Pasteur |
| authorships[5].institutions[0].id | https://openalex.org/I4210150276 |
| authorships[5].institutions[0].ror | https://ror.org/05wd66v55 |
| authorships[5].institutions[0].type | company |
| authorships[5].institutions[0].lineage | https://openalex.org/I3018075036, https://openalex.org/I4210150276 |
| authorships[5].institutions[0].country_code | MX |
| authorships[5].institutions[0].display_name | Sanofi (Mexico) |
| authorships[5].author_position | middle |
| authorships[5].raw_author_name | Tim Tibbitts |
| authorships[5].is_corresponding | False |
| authorships[5].raw_affiliation_strings | Sanofi Pasteur |
| authorships[6].author.id | https://openalex.org/A5021407297 |
| authorships[6].author.orcid | |
| authorships[6].author.display_name | Alice Raillard |
| authorships[6].countries | MX |
| authorships[6].affiliations[0].institution_ids | https://openalex.org/I4210150276 |
| authorships[6].affiliations[0].raw_affiliation_string | Sanofi Pasteur |
| authorships[6].institutions[0].id | https://openalex.org/I4210150276 |
| authorships[6].institutions[0].ror | https://ror.org/05wd66v55 |
| authorships[6].institutions[0].type | company |
| authorships[6].institutions[0].lineage | https://openalex.org/I3018075036, https://openalex.org/I4210150276 |
| authorships[6].institutions[0].country_code | MX |
| authorships[6].institutions[0].display_name | Sanofi (Mexico) |
| authorships[6].author_position | middle |
| authorships[6].raw_author_name | Alice Raillard |
| authorships[6].is_corresponding | False |
| authorships[6].raw_affiliation_strings | Sanofi Pasteur |
| authorships[7].author.id | https://openalex.org/A5033752856 |
| authorships[7].author.orcid | https://orcid.org/0000-0002-3562-7829 |
| authorships[7].author.display_name | Sylviane Gautheron |
| authorships[7].countries | MX |
| authorships[7].affiliations[0].institution_ids | https://openalex.org/I4210150276 |
| authorships[7].affiliations[0].raw_affiliation_string | Sanofi Pasteur |
| authorships[7].institutions[0].id | https://openalex.org/I4210150276 |
| authorships[7].institutions[0].ror | https://ror.org/05wd66v55 |
| authorships[7].institutions[0].type | company |
| authorships[7].institutions[0].lineage | https://openalex.org/I3018075036, https://openalex.org/I4210150276 |
| authorships[7].institutions[0].country_code | MX |
| authorships[7].institutions[0].display_name | Sanofi (Mexico) |
| authorships[7].author_position | middle |
| authorships[7].raw_author_name | Sylviane Gautheron |
| authorships[7].is_corresponding | False |
| authorships[7].raw_affiliation_strings | Sanofi Pasteur |
| authorships[8].author.id | https://openalex.org/A5023531481 |
| authorships[8].author.orcid | |
| authorships[8].author.display_name | Sheila Cummings |
| authorships[8].affiliations[0].raw_affiliation_string | Sanofi |
| authorships[8].author_position | middle |
| authorships[8].raw_author_name | Sheila Cummings |
| authorships[8].is_corresponding | False |
| authorships[8].raw_affiliation_strings | Sanofi |
| authorships[9].author.id | https://openalex.org/A5063202464 |
| authorships[9].author.orcid | https://orcid.org/0000-0002-9909-1146 |
| authorships[9].author.display_name | Dinesh S. Bangari |
| authorships[9].countries | US |
| authorships[9].affiliations[0].institution_ids | https://openalex.org/I4210111804 |
| authorships[9].affiliations[0].raw_affiliation_string | Sanofi (United States) |
| authorships[9].institutions[0].id | https://openalex.org/I4210111804 |
| authorships[9].institutions[0].ror | https://ror.org/027vj4x92 |
| authorships[9].institutions[0].type | company |
| authorships[9].institutions[0].lineage | https://openalex.org/I3018075036, https://openalex.org/I4210111804 |
| authorships[9].institutions[0].country_code | US |
| authorships[9].institutions[0].display_name | Sanofi (United States) |
| authorships[9].author_position | middle |
| authorships[9].raw_author_name | Dinesh Bangari |
| authorships[9].is_corresponding | False |
| authorships[9].raw_affiliation_strings | Sanofi (United States) |
| authorships[10].author.id | https://openalex.org/A5060102425 |
| authorships[10].author.orcid | https://orcid.org/0000-0003-3702-6207 |
| authorships[10].author.display_name | Swagata Kar |
| authorships[10].countries | US |
| authorships[10].affiliations[0].institution_ids | https://openalex.org/I4210105475 |
| authorships[10].affiliations[0].raw_affiliation_string | Bioqual, Inc. |
| authorships[10].institutions[0].id | https://openalex.org/I4210105475 |
| authorships[10].institutions[0].ror | https://ror.org/01na5rp93 |
| authorships[10].institutions[0].type | company |
| authorships[10].institutions[0].lineage | https://openalex.org/I4210105475 |
| authorships[10].institutions[0].country_code | US |
| authorships[10].institutions[0].display_name | Bioqual |
| authorships[10].author_position | middle |
| authorships[10].raw_author_name | Swagata Kar |
| authorships[10].is_corresponding | False |
| authorships[10].raw_affiliation_strings | Bioqual, Inc. |
| authorships[11].author.id | https://openalex.org/A5053002955 |
| authorships[11].author.orcid | https://orcid.org/0000-0002-7489-0232 |
| authorships[11].author.display_name | Caroline Atyeo |
| authorships[11].countries | US |
| authorships[11].affiliations[0].institution_ids | https://openalex.org/I2802422659 |
| authorships[11].affiliations[0].raw_affiliation_string | Ragon Institute of MGH, MIT, and Harvard |
| authorships[11].institutions[0].id | https://openalex.org/I2802422659 |
| authorships[11].institutions[0].ror | https://ror.org/053r20n13 |
| authorships[11].institutions[0].type | healthcare |
| authorships[11].institutions[0].lineage | https://openalex.org/I136199984, https://openalex.org/I2802422659, https://openalex.org/I4210087915, https://openalex.org/I48633490, https://openalex.org/I63966007 |
| authorships[11].institutions[0].country_code | US |
| authorships[11].institutions[0].display_name | Ragon Institute of MGH, MIT and Harvard |
| authorships[11].author_position | middle |
| authorships[11].raw_author_name | Caroline Atyeo |
| authorships[11].is_corresponding | False |
| authorships[11].raw_affiliation_strings | Ragon Institute of MGH, MIT, and Harvard |
| authorships[12].author.id | https://openalex.org/A5089717967 |
| authorships[12].author.orcid | https://orcid.org/0000-0002-4771-8058 |
| authorships[12].author.display_name | Yixiang Deng |
| authorships[12].countries | US |
| authorships[12].affiliations[0].institution_ids | https://openalex.org/I2802422659 |
| authorships[12].affiliations[0].raw_affiliation_string | Ragon Institute of MGH, MIT, and Harvard |
| authorships[12].institutions[0].id | https://openalex.org/I2802422659 |
| authorships[12].institutions[0].ror | https://ror.org/053r20n13 |
| authorships[12].institutions[0].type | healthcare |
| authorships[12].institutions[0].lineage | https://openalex.org/I136199984, https://openalex.org/I2802422659, https://openalex.org/I4210087915, https://openalex.org/I48633490, https://openalex.org/I63966007 |
| authorships[12].institutions[0].country_code | US |
| authorships[12].institutions[0].display_name | Ragon Institute of MGH, MIT and Harvard |
| authorships[12].author_position | middle |
| authorships[12].raw_author_name | Yixiang Deng |
| authorships[12].is_corresponding | False |
| authorships[12].raw_affiliation_strings | Ragon Institute of MGH, MIT, and Harvard |
| authorships[13].author.id | https://openalex.org/A5059371880 |
| authorships[13].author.orcid | https://orcid.org/0000-0002-7680-9215 |
| authorships[13].author.display_name | Galit Alter |
| authorships[13].countries | US |
| authorships[13].affiliations[0].institution_ids | https://openalex.org/I2802422659 |
| authorships[13].affiliations[0].raw_affiliation_string | Ragon Institute of MGH, MIT, and Harvard |
| authorships[13].institutions[0].id | https://openalex.org/I2802422659 |
| authorships[13].institutions[0].ror | https://ror.org/053r20n13 |
| authorships[13].institutions[0].type | healthcare |
| authorships[13].institutions[0].lineage | https://openalex.org/I136199984, https://openalex.org/I2802422659, https://openalex.org/I4210087915, https://openalex.org/I48633490, https://openalex.org/I63966007 |
| authorships[13].institutions[0].country_code | US |
| authorships[13].institutions[0].display_name | Ragon Institute of MGH, MIT and Harvard |
| authorships[13].author_position | middle |
| authorships[13].raw_author_name | Galit Alter |
| authorships[13].is_corresponding | False |
| authorships[13].raw_affiliation_strings | Ragon Institute of MGH, MIT, and Harvard |
| authorships[14].author.id | https://openalex.org/A5035380665 |
| authorships[14].author.orcid | |
| authorships[14].author.display_name | Cindy Gutzeit |
| authorships[14].countries | US |
| authorships[14].affiliations[0].institution_ids | https://openalex.org/I2802422659 |
| authorships[14].affiliations[0].raw_affiliation_string | Ragon Institute of MGH, MIT, and Harvard |
| authorships[14].institutions[0].id | https://openalex.org/I2802422659 |
| authorships[14].institutions[0].ror | https://ror.org/053r20n13 |
| authorships[14].institutions[0].type | healthcare |
| authorships[14].institutions[0].lineage | https://openalex.org/I136199984, https://openalex.org/I2802422659, https://openalex.org/I4210087915, https://openalex.org/I48633490, https://openalex.org/I63966007 |
| authorships[14].institutions[0].country_code | US |
| authorships[14].institutions[0].display_name | Ragon Institute of MGH, MIT and Harvard |
| authorships[14].author_position | middle |
| authorships[14].raw_author_name | Cindy Gutzeit |
| authorships[14].is_corresponding | False |
| authorships[14].raw_affiliation_strings | Ragon Institute of MGH, MIT, and Harvard |
| authorships[15].author.id | https://openalex.org/A5034726124 |
| authorships[15].author.orcid | https://orcid.org/0000-0002-4174-8424 |
| authorships[15].author.display_name | Marguerite Koutsoukos |
| authorships[15].affiliations[0].raw_affiliation_string | GSK Vaccines |
| authorships[15].author_position | middle |
| authorships[15].raw_author_name | Marguerite Koutsoukos |
| authorships[15].is_corresponding | False |
| authorships[15].raw_affiliation_strings | GSK Vaccines |
| authorships[16].author.id | https://openalex.org/A5068988278 |
| authorships[16].author.orcid | |
| authorships[16].author.display_name | Roman M. Chicz |
| authorships[16].countries | MX |
| authorships[16].affiliations[0].institution_ids | https://openalex.org/I4210150276 |
| authorships[16].affiliations[0].raw_affiliation_string | Sanofi Pasteur |
| authorships[16].institutions[0].id | https://openalex.org/I4210150276 |
| authorships[16].institutions[0].ror | https://ror.org/05wd66v55 |
| authorships[16].institutions[0].type | company |
| authorships[16].institutions[0].lineage | https://openalex.org/I3018075036, https://openalex.org/I4210150276 |
| authorships[16].institutions[0].country_code | MX |
| authorships[16].institutions[0].display_name | Sanofi (Mexico) |
| authorships[16].author_position | middle |
| authorships[16].raw_author_name | Roman Chicz |
| authorships[16].is_corresponding | False |
| authorships[16].raw_affiliation_strings | Sanofi Pasteur |
| authorships[17].author.id | https://openalex.org/A5043673432 |
| authorships[17].author.orcid | |
| authorships[17].author.display_name | Valérie Lecouturier |
| authorships[17].affiliations[0].raw_affiliation_string | Sanofi |
| authorships[17].author_position | last |
| authorships[17].raw_author_name | Valerie Lecouturier |
| authorships[17].is_corresponding | False |
| authorships[17].raw_affiliation_strings | Sanofi |
| has_content.pdf | True |
| has_content.grobid_xml | True |
| is_paratext | False |
| open_access.is_oa | True |
| open_access.oa_url | https://www.researchsquare.com/article/rs-1928234/latest.pdf |
| open_access.oa_status | gold |
| open_access.any_repository_has_fulltext | False |
| created_date | 2025-10-10T00:00:00 |
| display_name | A Beta-containing bivalent SARS-CoV-2 spike protein vaccine candidate with AS03 elicits durable and broad neutralization of variants including Omicron in macaques and confers protection in hamsters |
| has_fulltext | True |
| is_retracted | False |
| updated_date | 2025-11-06T03:46:38.306776 |
| primary_topic.id | https://openalex.org/T10118 |
| primary_topic.field.id | https://openalex.org/fields/27 |
| primary_topic.field.display_name | Medicine |
| primary_topic.score | 1.0 |
| primary_topic.domain.id | https://openalex.org/domains/4 |
| primary_topic.domain.display_name | Health Sciences |
| primary_topic.subfield.id | https://openalex.org/subfields/2725 |
| primary_topic.subfield.display_name | Infectious Diseases |
| primary_topic.display_name | SARS-CoV-2 and COVID-19 Research |
| related_works | https://openalex.org/W4205317059, https://openalex.org/W4224279380, https://openalex.org/W3176864053, https://openalex.org/W4206651655, https://openalex.org/W4292098121, https://openalex.org/W4210433452, https://openalex.org/W3036314732, https://openalex.org/W3084808338, https://openalex.org/W3196306939, https://openalex.org/W4285395912 |
| cited_by_count | 1 |
| counts_by_year[0].year | 2022 |
| counts_by_year[0].cited_by_count | 1 |
| locations_count | 1 |
| best_oa_location.id | doi:10.21203/rs.3.rs-1928234/v1 |
| best_oa_location.is_oa | True |
| best_oa_location.source | |
| best_oa_location.license | cc-by |
| best_oa_location.pdf_url | https://www.researchsquare.com/article/rs-1928234/latest.pdf |
| best_oa_location.version | acceptedVersion |
| best_oa_location.raw_type | posted-content |
| best_oa_location.license_id | https://openalex.org/licenses/cc-by |
| best_oa_location.is_accepted | True |
| best_oa_location.is_published | False |
| best_oa_location.raw_source_name | |
| best_oa_location.landing_page_url | https://doi.org/10.21203/rs.3.rs-1928234/v1 |
| primary_location.id | doi:10.21203/rs.3.rs-1928234/v1 |
| primary_location.is_oa | True |
| primary_location.source | |
| primary_location.license | cc-by |
| primary_location.pdf_url | https://www.researchsquare.com/article/rs-1928234/latest.pdf |
| primary_location.version | acceptedVersion |
| primary_location.raw_type | posted-content |
| primary_location.license_id | https://openalex.org/licenses/cc-by |
| primary_location.is_accepted | True |
| primary_location.is_published | False |
| primary_location.raw_source_name | |
| primary_location.landing_page_url | https://doi.org/10.21203/rs.3.rs-1928234/v1 |
| publication_date | 2022-09-02 |
| publication_year | 2022 |
| referenced_works | https://openalex.org/W4229442811, https://openalex.org/W4220724000, https://openalex.org/W4211251118, https://openalex.org/W4210920485, https://openalex.org/W4220677813, https://openalex.org/W4281681813, https://openalex.org/W3133782701, https://openalex.org/W3136475134, https://openalex.org/W3184341293, https://openalex.org/W3152885607, https://openalex.org/W2081305632, https://openalex.org/W2946773123, https://openalex.org/W3210828927, https://openalex.org/W3095217725, https://openalex.org/W3165479483, https://openalex.org/W3200674187, https://openalex.org/W3164640404, https://openalex.org/W3216208044, https://openalex.org/W3167555428, https://openalex.org/W4224232962, https://openalex.org/W3157876431, https://openalex.org/W3155578042, https://openalex.org/W3155004337, https://openalex.org/W3170325791, https://openalex.org/W4200629700, https://openalex.org/W3174017401, https://openalex.org/W4210272290, https://openalex.org/W4225369388, https://openalex.org/W4220761771, https://openalex.org/W3207427480, https://openalex.org/W3209429470, https://openalex.org/W4226469174, https://openalex.org/W4220886953, https://openalex.org/W4296026861, https://openalex.org/W4200601232, https://openalex.org/W3123160442, https://openalex.org/W4380852659, https://openalex.org/W4214532832, https://openalex.org/W3116925452, https://openalex.org/W3210049956, https://openalex.org/W4226229183, https://openalex.org/W3164260927, https://openalex.org/W3129956633 |
| referenced_works_count | 43 |
| abstract_inverted_index.a | 60, 87, 95, 165 |
| abstract_inverted_index.In | 133 |
| abstract_inverted_index.We | 49 |
| abstract_inverted_index.an | 22 |
| abstract_inverted_index.as | 118, 148, 150, 178, 180 |
| abstract_inverted_index.in | 24, 55, 86, 129, 156, 184 |
| abstract_inverted_index.is | 19 |
| abstract_inverted_index.of | 5, 11, 21, 71, 164 |
| abstract_inverted_index.or | 124 |
| abstract_inverted_index.to | 39, 120, 172 |
| abstract_inverted_index.Our | 159 |
| abstract_inverted_index.VOC | 112, 183 |
| abstract_inverted_index.and | 46, 52, 57, 75, 106, 116, 152, 175 |
| abstract_inverted_index.are | 37 |
| abstract_inverted_index.for | 16 |
| abstract_inverted_index.the | 3, 6, 66, 72, 76, 99, 121, 135, 162 |
| abstract_inverted_index.AS03 | 81 |
| abstract_inverted_index.Beta | 77, 125, 153 |
| abstract_inverted_index.CoV2 | 101, 168 |
| abstract_inverted_index.D614 | 74, 123 |
| abstract_inverted_index.have | 14 |
| abstract_inverted_index.more | 26 |
| abstract_inverted_index.preS | 84, 102, 169 |
| abstract_inverted_index.show | 93 |
| abstract_inverted_index.that | 94 |
| abstract_inverted_index.well | 149, 179 |
| abstract_inverted_index.with | 80, 98, 143 |
| abstract_inverted_index.(CoV2 | 83 |
| abstract_inverted_index.(VOC) | 13 |
| abstract_inverted_index.Alpha | 151 |
| abstract_inverted_index.BA.1, | 115 |
| abstract_inverted_index.D614G | 146 |
| abstract_inverted_index.Spike | 69 |
| abstract_inverted_index.broad | 41, 174 |
| abstract_inverted_index.there | 18 |
| abstract_inverted_index.using | 59 |
| abstract_inverted_index.viral | 141 |
| abstract_inverted_index.which | 17 |
| abstract_inverted_index.and/or | 29 |
| abstract_inverted_index.future | 47 |
| abstract_inverted_index.naïve | 130, 185 |
| abstract_inverted_index.severe | 27 |
| abstract_inverted_index.stable | 176 |
| abstract_inverted_index.strain | 147 |
| abstract_inverted_index.Omicron | 114 |
| abstract_inverted_index.achieve | 40 |
| abstract_inverted_index.against | 44, 111, 140, 182 |
| abstract_inverted_index.broader | 105 |
| abstract_inverted_index.concern | 12 |
| abstract_inverted_index.confers | 138 |
| abstract_inverted_index.current | 45 |
| abstract_inverted_index.durable | 107 |
| abstract_inverted_index.elicits | 104 |
| abstract_inverted_index.emerged | 15 |
| abstract_inverted_index.primary | 88, 96 |
| abstract_inverted_index.provide | 173 |
| abstract_inverted_index.reduced | 30 |
| abstract_inverted_index.several | 9 |
| abstract_inverted_index.strains | 79, 155 |
| abstract_inverted_index.studies | 54 |
| abstract_inverted_index.trimers | 70 |
| abstract_inverted_index.vaccine | 31, 35, 63 |
| abstract_inverted_index.variant | 126, 154 |
| abstract_inverted_index.COVID-19 | 7, 34 |
| abstract_inverted_index.adjuvant | 82 |
| abstract_inverted_index.antibody | 109 |
| abstract_inverted_index.bivalent | 61, 100, 136, 167 |
| abstract_inverted_index.compared | 119 |
| abstract_inverted_index.dTM-AS03 | 103, 170 |
| abstract_inverted_index.disease, | 28 |
| abstract_inverted_index.evidence | 20 |
| abstract_inverted_index.findings | 160 |
| abstract_inverted_index.hamsters | 58 |
| abstract_inverted_index.immunity | 43 |
| abstract_inverted_index.increase | 23 |
| abstract_inverted_index.macaques | 56 |
| abstract_inverted_index.parental | 73, 122, 145 |
| abstract_inverted_index.required | 38 |
| abstract_inverted_index.setting. | 90 |
| abstract_inverted_index.vaccines | 128 |
| abstract_inverted_index.variants | 10 |
| abstract_inverted_index.(B.1.351) | 78 |
| abstract_inverted_index.</bold>We | 92 |
| abstract_inverted_index.Effective | 33 |
| abstract_inverted_index.addition, | 134 |
| abstract_inverted_index.beginning | 4 |
| abstract_inverted_index.challenge | 53, 142 |
| abstract_inverted_index.conducted | 50 |
| abstract_inverted_index.dTM-AS03) | 85 |
| abstract_inverted_index.hamsters. | 157 |
| abstract_inverted_index.including | 113 |
| abstract_inverted_index.non-human | 131 |
| abstract_inverted_index.pandemic, | 8 |
| abstract_inverted_index.potential | 163 |
| abstract_inverted_index.primates. | 132 |
| abstract_inverted_index.responses | 110 |
| abstract_inverted_index.SARS-CoV-1 | 117 |
| abstract_inverted_index.SARS-CoV-2 | 67, 144 |
| abstract_inverted_index.containing | 65 |
| abstract_inverted_index.monovalent | 127 |
| abstract_inverted_index.protection | 139, 181 |
| abstract_inverted_index.protective | 42 |
| abstract_inverted_index.strategies | 36 |
| abstract_inverted_index.demonstrate | 161 |
| abstract_inverted_index.formulation | 64, 137, 171 |
| abstract_inverted_index.recombinant | 62 |
| abstract_inverted_index.</bold>Since | 2 |
| abstract_inverted_index.immunization | 89, 97 |
| abstract_inverted_index.neutralizing | 108 |
| abstract_inverted_index.populations. | 186 |
| abstract_inverted_index.<bold>Results | 91 |
| abstract_inverted_index.effectiveness. | 32 |
| abstract_inverted_index.immunogenicity | 51 |
| abstract_inverted_index.Beta-containing | 166 |
| abstract_inverted_index.immunogenicity, | 177 |
| abstract_inverted_index.<bold>Background | 1 |
| abstract_inverted_index.transmissibility, | 25 |
| abstract_inverted_index.prefusion-stabilized | 68 |
| abstract_inverted_index.<title>Abstract</title> | 0 |
| abstract_inverted_index.<bold>Conclusions</bold> | 158 |
| abstract_inverted_index.VOC.<bold>Methods</bold> | 48 |
| cited_by_percentile_year.max | 94 |
| cited_by_percentile_year.min | 89 |
| countries_distinct_count | 2 |
| institutions_distinct_count | 18 |
| sustainable_development_goals[0].id | https://metadata.un.org/sdg/3 |
| sustainable_development_goals[0].score | 0.8299999833106995 |
| sustainable_development_goals[0].display_name | Good health and well-being |
| citation_normalized_percentile.value | 0.44244567 |
| citation_normalized_percentile.is_in_top_1_percent | False |
| citation_normalized_percentile.is_in_top_10_percent | False |